US 8457988

I'll search for this patent and check for any CAFC 2026 docket activity.

US Patent 8,457,988 — Summary

Important note on scope: I searched for the specific number 8,457,988. I found no CAFC 2026 docket activity tied to this patent. What I did find is a well-documented PTAB and Federal Circuit history from 2015–2018 (detailed below). I am flagging this explicitly rather than presenting 2026 activity that I could not verify.

Bibliographic data (per the authoritative full text of US8457988B1)

Continuity: This patent is a division of US 13/013,680 (filed 2011-01-25, published as US20110119085A1), which is a continuation of US 12/704,097 (issued as US 7,895,059), which is a continuation of US 10/322,348 (issued as US 7,668,730), filed 2002-12-17.

⚠️ Discrepancies to note (not auto-corrected): The Google Patents record gives the priority date as 2002-12-17, while the Unified Patents portal entry for the same patent states 2002-12-16. I am reporting both literally. Also, one citing reference in the family (US20050090425A1) lists an assignee of Orphan Medical, Inc., reflecting the pre-Jazz lineage of this family.

Abstract (verbatim)

"A drug distribution system and method utilizes a central pharmacy and database to track all prescriptions for a sensitive drug. Information is kept in the database regarding all physicians allowed to prescribe the sensitive drug, and all patients receiving the drug. Abuses are identified by monitoring data in the database for prescription patterns by physicians and prescriptions obtained by patients. Further verification is made that the physician is eligible to prescribe the drug by consulting a separate database, and optionally whether any actions are taken against the physician. Multiple controls beyond those for normal drugs are imposed on the distribution depending on the sensitivity of the drug."

Independent claims — plain language

Claim 1 — A method of treating a narcoleptic patient with a prescription drug while controlling misuse/abuse/diversion, comprising: (a) receiving all prescription requests for narcoleptic patients at an exclusive central pharmacy from any/all doctors allowed to prescribe the drug, the requests containing patient identifiers, drug info, and doctor credentials; (b) requiring entry of that information into an exclusive computer database associated with the exclusive central pharmacy, such that the pharmacy and database are the only ones in existence for that drug and all prescriptions are processed only through them; (c) checking the doctors' credentials to confirm eligibility to prescribe; (d) confirming with the patient that educational material has been read before shipping; (e) checking the database for potential abuse; (f) providing the drug only if no potential abuse is found (by both patient and prescribing doctor); (g) confirming the patient received the drug; and (h) generating periodic reports via the database to evaluate diversion patterns.

Claim 9 — Substantively the same method, but the exclusive-central-pharmacy element is framed around the drug inventory being owned by a company (rather than the drug being "distributed by a company that obtained approval for distribution"). Claims 1 and 9 are otherwise textually parallel, and claims 10–15 depend from claim 9 in parallel to claims 2–8.

Dependent claims (2–8 / 10–15): distributed pharmacy/database with a query operating over all data (2, 10); authorizing dispensing by another pharmacy (3, 11); actually delivering the drug to treat the patient (4, 12); the exclusive central pharmacy enters the data (5, 13); selectively blocking shipment (6); blocking shipment when an abuse pattern is associated with the patient (7, 14); and the drug being a gamma hydroxy butyrate (GHB) drug product (8, 15).

Litigation / PTAB history (verified)

• CBM2014-00150 — Covered Business Method review of the '988 patent (not instituted – procedural).
• IPR2015-00551 — inter partes review of all claims (1–15) of the '988 patent, filed by Par Pharmaceutical, Inc./Amneal Pharmaceuticals. Consolidated in a joint Final Written Decision with IPR2015-00554 (US 7,668,730). A Final Written Decision issued July 27, 2016, holding the claims unpatentable as obvious.
• IPR2015-01814 and IPR2015-01817 — additional PTAB proceedings (Final Written Decisions).
• Federal Circuit: Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, 895 F.3d 1347 (Fed. Cir. 2018) — the court affirmed the Board's obviousness holdings for the '963 and '988 patents, including the distributed-database dependent limitations.

On the "CAFC 2026 docket" question

I found no CAFC docket from 2026 naming Patent 8,457,988. The most recent Federal Circuit sodium-oxybate litigation I could locate involving Jazz is Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC, Nos. 2024-2274, -2277, -2278 (Fed. Cir., decided May 6, 2025) — a REMS/injunction dispute that turned on patents such as US 11,147,782 and US 10,966,931, not the '988 patent. Because the '988 patent's claims were invalidated and its term expired on 2022-12-17, it is unlikely to be the subject of live 2026 Federal Circuit proceedings.

Uncertainty: My search results did not surface any 2026 Federal Circuit docket or PTAB filing specifically identifying 8,457,988, and search coverage of very recent dockets can lag. If you need a definitive "no 2026 CAFC activity" confirmations, that should be verified directly against PACER/CAFC docket records for the exact number.

I'll research the litigation history for US patent 8457988. Let me start with searches on the key litigation databases.

Let me gather more specific details on the identified cases.

Litigation Involving U.S. Patent No. 8,457,988 ("Sensitive drug distribution system and method")

Patent owner throughout: Jazz Pharmaceuticals, Inc. (later with Jazz Pharmaceuticals Ireland Limited). The '988 patent claims priority to Dec. 17, 2002 and is part of the Xyrem® (sodium oxybate/GHB) patent family. All listed matters below are tied specifically to the '988 patent (per the Google Patents litigation docket for US8457988B1 and the PTAB/CAFC records).

Below I distinguish what I could confirm from sources versus items that appear in the patent's litigation docket but for which I could not independently verify details.

1. District Court Litigation (Hatch‑Waxman / ANDA)

Sources: Google Patents docket links for US8457988B1 (Unified Patents litigation data); Docket Alarm consolidation stipulation (No. 2:13-cv-00391); Wockhardt answer/counterclaim (paragraphfour.com, D.N.J. 2:15-cv-05619).

Caveat on items 6–9: These case numbers appear in the Google Patents/Unified Patents litigation feed associated with the '988 patent, but I could not independently verify the defendants, filing dates, or outcomes from the sources I retrieved. I flag them as unverified rather than asserting details I do not have.

2. PTAB Proceedings (specific to the '988 patent)

Sources: PTAB Final Written Decision (IPR2015-00551 / IPR2015-00554, July 27, 2016); PTAB Decision instituting IPR2015-01814 and granting joinder (Oct. 30, 2015); RPX Insight; RPX/Patexia docket records.

Panel for the '988 IPRs: Administrative Patent Judges Jacqueline Wright Bonilla, Brian P. Murphy (opinion author), and Jon B. Tornquist (IPR2015-01814 panel also included Susan L. C. Mitchell).

3. Federal Circuit Appeal

Sources: Duane Morris LLP client alert (July 2018); Fed. Cir. opinion (govinfo, USCOURTS-ca13-17-01675); CourtListener opinion Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC. Par settled during the appeal and was no longer a party; Wockhardt also settled before the decision.

4. Overall Outcome of the '988 Patent

• The claims of U.S. 8,457,988 were held unpatentable by the PTAB (IPR2015-00551/-01817) and that decision was affirmed by the Federal Circuit on July 13, 2018.
• Per the Google Patents legal-status record, the patent has an anticipated expiration date of Dec. 17, 2022 and is currently "Expired – Fee Related."

Items I could not confirm (stated explicitly rather than guessed)

1. The defendants and outcomes in D.N.J. 2:15-cv-06548, 2:17-cv-05487, and 2:18-cv-00029, and E.D.N.Y. 2:17-cv-04439 — these appear in the patent's litigation docket but I could not verify party details.
2. The exact Federal Circuit docket number(s) for the '988 appeal — sources variously reference 2017-1671 and 2017-1675 (the appeal covered multiple consolidated IPRs), and I did not fully confirm which number maps specifically to the '988 portion.
3. Whether any of the unverified district court cases resulted in a judgment on the '988 patent specifically, as opposed to the '988 patent being one of several patents-in-suit in a consolidated action.

Recommendation for definitive verification: the underlying dockets should be pulled from PACER (D.N.J. 2:13-cv-00391 consolidated docket and the individual case numbers above) and from PTAB E2E / Docket Alarm / RPX Insight for the IPR records (IPR2015-00551, -01814, -01817; CBM2014-00150). I have not relied on any number similar to but different from 8,457,988.

AIA Trial Proceedings — US Patent 8,457,988 ("Sensitive drug distribution system and method")

⚠️ Data-source conflict — flagged, not reconciled. The structured "PTAB proceedings on file" block in this prompt states that the USPTO ODP API returns no AIA trial proceedings for this patent. That is wrong as a factual matter. The authoritative full text of US8457988B1 in the same prompt lists four AIA proceedings in its own "Family has litigation" block — CBM2014-00150, IPR2015-00551, IPR2015-01814, IPR2015-01817 — and all four are independently verified against PTAB decisions, the Federal Circuit opinion, and third-party dockets (below). I am treating the patent text + verified decisions as controlling and the ODP "no activity" return as an indexing gap (these are 2014–2015 trial numbers; they post-date the ODP ingest scope for this record, and the patent's "Expired – Fee Related" status likely suppressed the trial field). Do not rely on the ODP block for this patent. No proceeding number below is invented; every one appears in the patent record or a cited decision.

Proceedings overview

Four AIA trial proceedings: one CBM (institution denied 2015-01-13) and three IPRs (IPR2015-00551 instituted 2015-07-28; IPR2015-01814 and IPR2015-01817 instituted as § 315(c) joinders), with all 15 claims of the '988 patent held unpatentable on 2016-07-27 and that holding affirmed on 2018-07-13. Nothing is pending. Bottom line for a defendant: claims 1–15 are dead — any demand letter or complaint asserting US 8,457,988 is asserting a canceled patent, and continuing to press it invites Rule 11 exposure. The only nuance worth knowing is that claim 9 (the "inventory owned by a company" independent claim) was invalidated on the same two ACA-based grounds as claim 1, so there is no fallback independent claim to retreat to.

IPR2015-00551 — Par Pharmaceutical, Inc. & [Amneal Pharmaceuticals, LLC](/litigations/by-plaintiff/Amneal%20Pharmaceuticals%2C%20LLC) v. Jazz Pharmaceuticals, Inc.

• Type: Inter Partes Review (lead case; consolidated for decision with IPR2015-00554 on the '730 patent)
• Filed: 2015-01-08
• Status: Final Written Decision issued 2016-07-27 (verbatim in the record: "Final Decision: Final Written Decision IPR2015 00551 (P.T.A.B. Jul. 27, 2016)"); followed by a Decision Denying Patent Owner's Request for Rehearing (P.T.A.B. Dec. 22, 2016), Paper 74. Certificate of cancellation followed affirmance.
• Judge panel: Jacqueline Wright Bonilla, Brian P. Murphy, Jon B. Tornquist (Murphy authored); same panel handled the paired '730 case.
• Petition grounds: two grounds under 35 U.S.C. § 103(a) against all 15 claims:
  • Ground 1 — claims 1, 3–9, 11–15 obvious over the "Advisory Committee Art" (ACA materials, Exs. 1003–1006): the Xyrem® FDA advisory-committee transcript/slides, the FDA preliminary clinical safety review, the Xyrem® briefing booklet, and the video/transcript of the proposed distribution system.
  • Ground 2 — claims 2 and 10 obvious over the ACA materials in view of Korfhage (Ex. 1037) (distributed database).
  • Art was pre-AIA § 102(b) printed-publication prior art, critical date 2001-12-17.
• Institution decision: Instituted 2015-07-28 (IPR2015-00551 & -00554, Paper 19/20; the Board's Dec. on Inst. runs to ~42 pages). The Board found a reasonable likelihood as to all challenged claims and instituted on both grounds for all claims 1–15. Patent Owner's § 312(a)(2) real-party-in-interest attack (failure to name Par's parent companies) was raised and rejected.
• Final Written Decision (2016-07-27): Claims 1–15 — every claim of the '988 patent — held unpatentable. Verbatim from the FWD: "we determine Petitioner has shown by a preponderance of the evidence that claims 1–11 of the '730 patent and claims 1–15 of the '988 patent are unpatentable." No claim survived. Key subordinate holdings:
  • Claim construction: "periodic reports" construed to mean reports "generated at regular intervals or intermittently" (rejecting Jazz's regular-frequency-only reading); "information identifying patients" construed as argued by the Board.
  • Claims 2 and 10: the Board credited Amneal's expert that distributed database systems "were well-known in the art," found Korfhage disclosed a database distributable over multiple computers, and held the limitation obvious as "a predictable use of a known distributed data system according to its established function" (citing KSR, 550 U.S. 398, 417).
• Settlement / termination: No settlement as to Par/Amneal at the PTAB stage. Par later settled during the Federal Circuit appeal (see below). The Wockhardt side did settle — see IPR2015-01814.
• Appeal: Yes. Consolidated appeal Nos. 2017-1671, -1673, -1674, -1675, -1676, -1677, -2075 (the -2071/-1675 line corresponds to this group). Decision: Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, 895 F.3d 1347 (Fed. Cir. 2018), decided 2018-07-13 (Lourie, J.). Affirmed. The court (i) held it had jurisdiction notwithstanding the Board's pre-SAS partial institution, applying PGS Geophysical AS v. Iancu, 891 F.3d 1354 (Fed. Cir. 2018), since neither party requested SAS-based relief; (ii) affirmed that the ACA materials were publicly accessible printed publications under § 102(b) — the Federal Register notice "widely disseminated" the materials, a person of ordinary skill "would have been familiar with the Federal Register and motivated to look for notices related to drug distribution, safety, or abuse prevention," and indexing/searchability is not required; and (iii) affirmed the claim constructions and the obviousness holdings, including that distributing the ACA database was a predictable use of a known distributed system. Opinion: https://www.courtlistener.com/opinion/[4516711](/patent/4516711)/jazz-pharmaceuticals-inc-v-amneal-pharmaceuticals-llc/ ; PDF: https://www.govinfo.gov/content/pkg/USCOURTS-ca13-17-01675/pdf/USCOURTS-ca13-17-01675-0.pdf
• Defensive value: Decisive. The lead IPR killed all 15 claims and survived full appellate review. A defendant facing a '988 assertion can move for judgment on the pleadings or Rule 12(b)(6) and cite the FWD + the Fed. Cir. affirmance. The invalidity theory is fully public (ACA materials + Korfhage) and reusable.

FWD PDF (representative '730/'988 decision): https://ipwatchdog.com/wp-content/uploads/2018/01/730-final-written-decision.pdf · Institution decision: https://paragraphfour.com/uploads/cases15/ipr15-0551IRD.pdf

IPR2015-01817 — Amneal Pharmaceuticals LLC v. Jazz Pharmaceuticals, Inc.

• Type: Inter Partes Review — filed as a copycat petition + Motion for Joinder under 35 U.S.C. § 315(c)
• Filed: 2015-08-26
• Status: Institution of Inter Partes Review and Grant of Motion for Joinder; Final Written Decision entered 2016-07-27 (record: "IPR2015-01817, No. 14 Final Decision – Final Written Decision IPR2015 00551 (P.T.A.B. Jul. 27, 2016)")
• Judge panel: Jacqueline Wright Bonilla, Susan L. C. Mitchell, Brian P. Murphy (Bonilla authored the joinder decision)
• Petition grounds: § 103(a) only, on "same prior art, same exhibits, same expert declaration, and same claim construction positions" as IPR2015-00551 — i.e., ACA materials for claims 1, 3–9, 11–15 and ACA + Korfhage for claims 2 and 10. All 15 claims challenged.
• Institution decision: Instituted 2015-12-10, with joinder granted. The Board noted Amneal's petition was based only on the identical grounds already instituted in IPR2015-00551 (and already joined by Wockhardt's IPR2015-01814), and that it was filed within one month of the 2015-07-28 institution — satisfying 37 C.F.R. § 42.122(b) timing. Joinder factors (trial schedule impact, cost, discovery, simplification) favored grant.
• Final Written Decision: The same 2016-07-27 FWD holding claims 1–15 unpatentable was entered in this case by operation of the joinder.
• Settlement / termination: None as to Amneal.
• Appeal: Rolled into the consolidated Fed. Cir. appeal Nos. 2017-1671 et al., affirmed at 895 F.3d 1347.
• Defensive value: Confirms the ACA/Korfhage grounds are the only grounds that mattered, and confirms Amneal self-joined rather than running new art — meaning no additional invalidity art was developed in this track beyond the ACA materials.

Joinder/institution decision: https://www.docketalarm.com/cases/PTAB/IPR2015-01817/Inter_Partes_Review_of_U.S._Pat._8457988/docs/12-10-2015-Board/Decision_Granting_Institution-12-Decision_Institution_of_Inter_Partes_Review_and_Grant_of_Motion_for_Joinder.pdf?download=true

IPR2015-01814 — Wockhardt Bio AG v. Jazz Pharmaceuticals, Inc.

• Type: Inter Partes Review — § 315(c) joinder into IPR2015-00551
• Filed: 2015-08-27
• Status: Institution decision 2015-10-30; "Order – Termination of the Proceedings as to Petitioner Wockhardt Bio AG (P.T.A.B. May 5, 2016)"; Final Written Decision entered 2016-07-27 (record: "IPR2015-01814, No. 12 Final Decision – Final Written Decision IPR2015 00551")
• Judge panel: Jacqueline Wright Bonilla, Susan L. C. Mitchell, Brian P. Murphy (Bonilla, Mitchell, Murphy listed; Murphy on the FWD panel)
• Petition grounds: § 103(a) over the ACA materials on the same instituted grounds; all 15 claims challenged.
• Institution decision: Instituted 2015-10-30 with joinder granted to IPR2015-00551 (the Board noted at the time of the Amneal joinder that IPR2015-00551 had "previously been joined with IPR2015-01814 in relation to a Petition filed by a different Petitioner, Wockhardt").
• Final Written Decision: Wockhardt exited before the FWD. After the oral hearing, on the parties' joint request (Paper 64), the Board ordered termination of all six Wockhardt proceedings and granted the parties' request to treat the underlying settlement agreement as business confidential information (Paper 65). Wockhardt's parallel termination request covered IPR2015-00545/-00546/-00547/-00548/-00551/-00554 and IPR2015-01813/-01814/-01815/-01816/-01818/-01820 and IPR2016-00370.
• Settlement / termination: Settled — terms confidential. Jazz and Wockhardt entered a confidential settlement agreement; the Board granted the request to keep it business-confidential under 35 U.S.C. § 317(b) / 37 C.F.R. § 42.74(b)–(c).
• Appeal: None by Wockhardt; the FWD entered in this case is the same 2016-07-27 decision that Jazz appealed in Nos. 2017-1671 et al. (Par having settled out of the appeal on 2018-01-19, ECF No. 51 in No. 17-1671).
• Defensive value: Establishes that a defensive-aggregator-style joiner existed in the chain, but Wockhardt bought its way out. The substantive outcome is unchanged: the joined proceeding produced the same all-claims-invalid FWD.

CBM2014-00150 — Par Pharmaceutical, Inc., Roxane Laboratories, Inc. & Amneal Pharmaceuticals, LLC v. Jazz Pharmaceuticals, Inc.

• Type: Covered Business Method review (AIA § 18; 35 U.S.C. § 321)
• Filed: 2014-07-07 (per the patent record and the Board's related-cases list: "CBM2014-00150 (filed July 7, 2014) (US 8,457,988 B1)")
• Status: Denying Institution of Covered Business Method Patent Review, 37 C.F.R. § 42.208 (P.T.A.B. 2015-01-13) — "Not Instituted – Procedural" per the patent record.
• Judge panel: Lora M. Green, Brian P. Murphy, Jon B. Tornquist (Murphy authored)
• Petition grounds: Claims 1–15 challenged as unpatentable under 35 U.S.C. §§ 101, 102(b), and 103(a) (the § 101 abstract-idea theory was the headline ground, post-Alice).
• Institution decision: Denied 2015-01-13. The Board applied the four CBM cases (CBM2014-00149/-00150/-00151/-00153) together, treating CBM2014-00151 (the '730 patent) as representative. Reasoning: petitioner failed to show the patent is a "covered business method patent" under AIA § 18(d)(1), i.e., that it claims a method "used in the practice, administration, or management of a financial product or service." The Board held the claims recite checks and controls on shipping/providing a prescription drug to prevent abuse and diversion, not the movement of money or extension of credit; the specification's insurance-coverage and ability-to-pay steps are not recited in the claims; and CBM review does not extend to any business method merely "used in commerce."
• Final Written Decision: N/A — never instituted.
• Settlement / termination: N/A.
• Appeal: None (no institution = no FWD to appeal).
• Defensive value: A dead end — but a useful negative signal. It means a § 101/abstract-idea CBM theory against this family was tried and rejected at the institution threshold, so don't expect a CBM-style § 101 argument to carry weight. The winning path was always the § 103 printed-publication route in the IPRs.

CBM denial PDF: https://ptabtrialblog.com/wp-content/uploads/2015/01/CBM2014-00149-150-151-153-Denying-Institution-of-Cover-Business-Method-Review-20150113.pdf

Strategic summary

Claim status — all canceled, nothing sustained. US 8,457,988 issued with claims 1–15: independent claims 1 and 9 and dependent claims 2–8 and 10–15. In IPR2015-00551 the Board held all of claims 1–15 unpatentable (FWD 2016-07-27), and the Federal Circuit affirmed on 2018-07-13, 895 F.3d 1347. There is no surviving claim and no untested claim — the joinder cases (IPR2015-01814, IPR2015-01817) challenged the same 1–15 on the same grounds, so nothing was left unaddressed. (Careful drafting point: the FWD's own words are "unpatentable," not "canceled"; the cancellation certificate issues after appeal. Subsequent litigation filings in the family describe the end state bluntly: "The result of inter partes review, as affirmed by the Federal Circuit, was the invalidation of all the patents in the '730 family.") Notably, claim 9 — the "inventory is owned by a company" variant — was not spared; it fell on the same two grounds.

Estoppel landscape. For a defendant today the practical answer is that § 315(e)(2) is academic: you cannot infringe a canceled claim. But the estoppel mapping matters if anyone tries to assert a sibling in the family (e.g., US 7,668,730, 7,765,106, 7,765,107, 7,895,059, 8,589,182, 8,731,963 — all of which also went down in the same consolidated appeal). The petitioners here — Par, Amneal, Roxane, and Wockhardt — and their privies are estopped under § 315(e)(2) from raising in a civil action any ground they raised or reasonably could have raised, which for these patents is essentially the entire ACA/Korfhage universe. A new, unrelated defendant is not personally estopped, but it inherits a fully built, judicially blessed invalidity record: the ACA materials are now binding precedent-level prior art for this family under Jazz v. Amneal. Any fresh IPR on the '988 patent is barred anyway — the patent's claims are gone and the term expired 2022-12-17.

Pattern signals. (1) Coordinated generic attack. Par, Amneal, and Roxane filed in lockstep — the four CBM petitions (CBM2014-00149/-00150/-00151/-00153, plus -00161 and -00175 on the '106/'107 patents) failed institution on 2015-01-13, and the same parties pivoted to IPRs within days (Par/Amneal on 2015-01-08 for '730/'988). (2) Follow-on joining petitioners. Both Wockhardt (IPR2015-01814, filed 2015-08-27) and Amneal (IPR2015-01817, filed 2015-08-26) filed near-verbatim copycat petitions with motions for joinder within one month of the 2015-07-28 institution — textbook "free ride on the lead petitioner's art" behavior. (3) Defensive aggregator? Wockhardt Bio AG (a generics manufacturer, joined by its bio-subsidiary) functioned as an additional challenger, but there is no Unified Patents or similar aggregator in this chain; the patent record's docket links to the Unified Patents portal are references to Unified's litigation database, not to Unified as petitioner. (4) Patent owner posture. Jazz litigated aggressively before the PTAB and then appealed every adverse FWD — the consolidated appeal covered six FWDs and seven patents — and lost across the board. Jazz did settle out Par (appeal, 2018-01-19) and Wockhardt (PTAB, 2016-05-05, confidential), but the substantive rulings were not bought out: Amneal stayed in and the Federal Circuit decided the merits.

Recommended next steps

If you are a defendant and the patent has claims invalidated: Do not treat this as a negotiation. Pull the FWD and the affirmance, and put them in the first responsive filing.

• The operative disposition, quoted: "we determine Petitioner has shown by a preponderance of the evidence that claims 1–11 of the '730 patent and claims 1–15 of the '988 patent are unpatentable" — Par Pharm., Inc. v. Jazz Pharms., Inc., IPR2015-00551, Paper 70 (P.T.A.B. Jul. 27, 2016) (FWD). FWD PDF: https://ipwatchdog.com/wp-content/uploads/2018/01/730-final-written-decision.pdf
• The affirmance: Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, 895 F.3d 1347 (Fed. Cir. 2018) (decided 2018-07-13; Nos. 2017-1671, -1673, -1674, -1675, -1676, -1677, -2075). https://www.courtlistener.com/opinion/4516711/jazz-pharmaceuticals-inc-v-amneal-pharmaceuticals-llc/
• Practical use: attach the two documents to a Rule 12(b)(6)/12(c) motion, or to a pre-motion letter, and state that every claim of US 8,457,988 has been held unpatentable and the holding affirmed. If a demand letter cites claim 1, 2, 8, 9, or 15 (the GHB-product claim), it is citing a canceled claim — preserve the letter, and consider a Rule 11 / § 285 posture.

Active proceedings: None. No live PTAB trial, no pending appeal, no § 315(d) concurrent-proceeding issue. Trial-stage milestones (1-year FWD deadline, institution deadline, oral hearing) are all in the past — the last FWD date was 2016-07-27 and the last appellate mandate followed the 2018-07-13 decision. The patent is "Expired – Fee Related" with an anticipated expiration of 2022-12-17.

On the ODP gap: the "no PTAB activity on file" return in the structured block should be treated as a false negative, corrected here. If you need a formal verification artifact for a filing, pull each of CBM2014-00150, IPR2015-00551, IPR2015-01814, IPR2015-01817 individually from USPTO PTAB E2E / Patent Trial and Appeal Board End-to-End (https://ptacts.uspto.gov/ptacts/) rather than relying on the ODP trial-proceedings field for this patent.

One open item I could not fully verify: the exact identity of the third panel member on the IPR2015-00551 institution decision (as opposed to the FWD panel of Bonilla/Murphy/Tornquist, which is confirmed from the FWD caption, and the CBM panel of Green/Murphy/Tornquist, confirmed from the CBM denial caption). The FWD panel is the one that matters for the invalidity holding, and that is verified.

I'll research the assignment chain for US 8,457,988, starting with the USPTO assignment records and the corporate history of the original assignee.

Let me dig into the specific assignment records and reel/frame numbers for this patent.

Assignment & Ownership Reconstruction — US 8,457,988

Data-quality note up front. The USPTO Assignment Center (assignmentcenter.uspto.gov) was not directly queryable in this session; the assignment facts below are reconstructed from the Google Patents legal-events panel for US8457988B1 (authoritative here) plus corroborating records surfaced for sibling members of the same family. Where I could only obtain a reel/frame for a sibling application rather than for '988 itself, I say so explicitly. I did not invent any reel/frame numbers.

Inventors

Basis for "Orphan Medical": The earliest application in this family — US 10/322,348 — was filed 2002-12-17 and published as US20050090425A1, whose listed assignee is Orphan Medical, Inc. The inventors' Twin Cities–metro residences are consistent with Orphan Medical's Minnetonka, MN headquarters. I could not retrieve the recorded inventor→company assignment instrument itself, so the employer attribution is inferential, not documentary.

Pattern check: No unusual pattern. This is the ordinary case — all inventors are co-located with, and assigned to, the operating company that filed the application. There is no evidence of inventors departing the original assignee within 12 months (the classic pre-fire-sale tell). The Minneapolis-area inventor group simply stayed with the asset as it moved from Orphan Medical to Jazz.

Original assignee

• Entity named on the issued patent: Jazz Pharmaceuticals, Inc. (Palo Alto, CA) — per the printed patent front page / Justia.
• Entity that actually filed the underlying application (2002): Orphan Medical, Inc., a Minnesota specialty-drug company. The corporate lineage is Orphan Medical → acquired by Jazz in 2005.
• Product embodying the claims: Yes. The claims recite a restricted-distribution method for a narcolepsy drug; Xyrem® (sodium oxybate/GHB) is the commercial embodiment and the reason the patent exists. Xyrem generated ~$1.6 B in 2019 revenue (roughly three-quarters of Jazz's product revenue).
• Primary line of business: Specialty biopharmaceuticals (CNS/neurology, sleep, oncology).
• Current status: Operating. Jazz is now a NASDAQ-listed company under Jazz Pharmaceuticals plc (Irish parent, US operating sub Jazz Pharmaceuticals, Inc.). Orphan Medical survives only as a wholly-owned subsidiary.
• Corporate event relevant to the chain: Jazz acquired Orphan Medical via a reverse merger (Agreement and Plan of Merger dated 2005-04-18, closing 2005-06-24), ~$122.6 M announced / ~$145.4 M cash consideration per the Jazz 10-K. In 2009 Jazz was near bankruptcy and replaced its management team — but that was a Jazz-internal distress event, not a patent bankruptcy sale (see signal 6 below).

Assignment timeline

Google Patents records two post-issuance assignment events naming the '988 patent, both liens recorded by banks / releases of those liens — not ownership transfers. Plus the pre-issuance corporate lineage (Orphan Medical → Jazz), which is an acquisition, not a recorded patent assignment I could pull for '988 itself.

Correspondent of record: Not determinable from the sources retrieved. This is the single most important field the task asks for and I could not obtain it for any link in this chain. No correspondent name/firm can therefore be reported or flagged as recurring — and I will not guess one. To complete this field, pull the four recordings above from USPTO Assignment Center, which lists correspondent of record per recording.

Additional July 2015 recordings (unverified): A sibling family application's assignment record (app 14/219,904) shows three further entries — 36123/0334 (2015-07-17, "Assignment of Assignors Interest (see document for details)") and 36194/0448 and 36194/0986 (both 2015-07-28). I could not retrieve the parties or conveyance substance for these, so I do not characterize them. If they are intra-Jazz ownership assignments, they belong in the chain; if they are ancillary filings to the BofA security agreement, they do not. Flagged as a gap, not a finding.

Discrepancy with the prior section (flagged, not auto-corrected): The earlier summary states the current assignee is "Jazz Pharmaceuticals Inc"; the Unified Patents page for sibling patent US 7,895,059 lists "Jazz Pharmaceuticals Ireland Ltd." Both appear literally in the sources. The Google Patents panel for '988 itself lists Jazz Pharmaceuticals Inc, so I treat that as the '988-specific answer while noting the family-wide assignee drift toward the Irish entity.

Timeline diagram

timeline
    title Ownership of US 8457988
    2002 : Filed by Orphan Medical
    2005 : Orphan Medical acquired by Jazz
    2012 : Divisional application filed
    2013 : Patent US 8457988 issued to Jazz
    2015 : Bank of America collateral lien
    2021 : BofA lien released
         : U S Bank collateral lien recorded
    2022 : Patent term expired

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT. No "IP/Holdings/Licensing/Ventures" LLC ever appears as assignee. The only non-Jazz entities in the chain are Bank of America, N.A. (reel 35936/0200) and U.S. Bank National Association — lenders taking collateral, not licensing shells.

2. Known asserter in the chain — NOT PRESENT. Jazz Pharmaceuticals, Inc. matches no entry on the Acacia / Marathon / IV / Wi-LAN / Conversant / Vringo / Pendrell / Round Rock / Spangenberg lists. Jazz is the quintessential operating-company plaintiff (it sells Xyrem and sued generics directly).

3. Repeat correspondent across the chain — UNCLEAR / UNVERIFIABLE. Correspondent data was not retrievable this session. No recurrence can be asserted, and per the brief, a single appearance would not be a finding anyway. Requires Assignment Center lookup.

4. Cascading transfers — NOT PRESENT. Zero chained LLC transfers. The two recorded events involving non-Jazz parties are 2015-06-19 → 2021-05-05 (≈6 years apart), a lien and its release, not a cascade.

5. Pre-litigation transfer — NOT PRESENT. The first ANDA suits (D.N.J. 2:13-cv-00391, filed 2013-01-18) predate the 2015-06-19 security agreement by ~2.5 years. The lien did not precede litigation.

6. Bankruptcy fire-sale — NOT PRESENT. Although Jazz was near bankruptcy circa 2009 and replaced management, the '988 asset was never sold in a bankruptcy proceeding. Orphan Medical was acquired in a solvent stock-for-cash merger in 2005, and the patent stayed inside Jazz through to expiry.

7. Privateering — NOT PRESENT. No operating-company→NPE transfer. Jazz asserted its own patents, in its own name, against actual generic competitors — the opposite of privateering.

8. Defensive aggregator — NOT PRESENT. The chain does not terminate at RPX, AST, LOT, Unified, or OIN. It terminates at Jazz (with a bank collateral lien), then at expiry.

Verdict

Operating-company assertion.

Justification: every recorded event in the chain runs in favor of an operating patentee. The patent was filed by Orphan Medical (2002) and passed to Jazz Pharmaceuticals, Inc. by the 2005 merger/acquisition; the only two post-issuance recordings — reel 35936/0200 (Bank of America security agreement, 2015-06-19) and reel 56150/0708 (release, 2021-05-05) plus the replacement U.S. Bank security agreement (2021-05-05) — are collateral liens and their discharge, not transfers to an asserter. Jazz shipped Xyrem® embodying the claims and asserted the patent itself against ANDA filers (D.N.J. 2:13-cv-00391 et al.), so this is direct operating-company enforcement, not NPE activity. Note the terminal caveat for completeness: the claims were held unpatentable (PTAB IPR2015-00551 FWD, 2016-07-27; affirmed Jazz v. Amneal, 895 F.3d 1347 (Fed. Cir. 2018)) and the patent expired 2022-12-17, so the asset is now inert.

Verification links:

• USPTO Assignment Center search by patent number: https://assignmentcenter.uspto.gov/
• Google Patents legal events (source for the 2015/2021 entries above): https://patents.google.com/patent/US8457988/en
• Sibling application assignment record used for the reel/frame corroboration (app 14/219,904): https://www.plainsite.org/patents/application/14219904/

Open items to close (stated rather than guessed): (i) correspondent of record for reels 35936/0200, 56150/0708 and the 2021 U.S. Bank agreement; (ii) parties and substance of the July 2015 recordings 36123/0334, 36194/0448, 36194/0986; (iii) confirmation that the 2015 and 2021 bulk lien reels actually cover US 8,457,988 by name.

I'll research this systematically. Let me start with searches to verify the patent and its cited prior art.

I have the authoritative citation lists from the patent text. Let me verify a few of the most relevant references to describe them accurately.

Let me verify a couple of specifics — the "Lilly" reference used in the IPR and the Elsayed reference.

Prior-Art Analysis — U.S. Patent No. 8,457,988 B1

"Sensitive drug distribution system and method" (Jazz Pharmaceuticals / original lineage: Orphan Medical)

Note: I have reached the maximum number of tool calls, so the analysis below is built from the authoritative full text of US8457988B1 (supplied in the task) plus the search results I retrieved before that limit. Where I could not independently verify a detail, I say so rather than filling it in.

0. Two framing points before the reference-by-reference table

(A) The patent was never invalidated under § 102 — it fell under § 103 (obviousness). This matters because the task asks which references "potentially anticipate" under § 102. The authoritative record shows:

• The examiner allowed the parent claims specifically because "[t]he closest prior art of record does not teach or fairly suggest that all prescriptions for GHB [Xyrem] are processed only by the exclusive central pharmacy using only the exclusive computer database." (Examiner's Reasons for Allowance of the '730 patent, quoted in the IPR2015‑00551 record.)
• The PTAB then held claims 1–15 of the '988 patent unpatentable under 35 U.S.C. § 103(a) — obvious — in the joint Final Written Decision of July 27, 2016 (IPR2015‑00551 / IPR2015‑00554), affirmed by the Federal Circuit in Jazz Pharmaceuticals, Inc. v. [Amneal Pharmaceuticals, LLC](/litigations/by-plaintiff/Amneal%20Pharmaceuticals%2C%20LLC), 895 F.3d 1347 (Fed. Cir. 2018).
• The actual invalidating art was NOT primarily the patent citations at all — it was the "Advisory Committee Art" (ACA), a set of FDA non-patent publications (see § 2 below). Several patent citations (Elsayed, Lilly, Korfhage) were used only as secondary § 103 references.

(B) Pre-AIA statute applies. Because the '988 patent carries a 2002‑12‑17 priority date, pre-AIA §§ 102/103 govern. Consequently many of the cited 2003–2004 publications are NOT § 102(a)/(b) art on their publication date; they are cited as § 102(e) art (U.S. applications/patents with earlier effective filing dates) or as § 103 background. I note this per-reference where relevant.

1. Master table of patent citations listed on US 8,457,988

Google Patents lists 62 examiner citations ("Patent Citations (62)") and a broader 44-item "Citations" set. The full-text dump supplied to me truncates the 62-list partway through; I have enumerated everything visible in both lists. Columns: Ref | Effective/published date | Issue date | Assignee/Applicant | Description | § 102 relevance to '988 claims.

1.1 Early mechanical/institutional dispensing art (background; no § 102 relevance)

1.2 Electronic prescribing / pharmacy-management art

1.3 The most relevant patent citations (controlled-distribution / abuse-monitoring art)

1.4 Remaining cited publications (2001–2004; generally § 102(e)/background)

Observation from the citation profile: The examiner's set is dominated by generic e-prescribing, EMR, and inventory-management art. Only a handful (Elsayed '501, Williams '720, McQuade '762/'681, Lilly '295, Fetterman '126) actually address controlled distribution or abuse-risk monitoring — and none discloses the '988 patent's key distinguishing limitation (a single, exclusive central pharmacy operating the only database in existence for the drug).

2. The art that actually mattered: the "Advisory Committee Art" (non-patent)

From the IPR2015‑00551 Final Written Decision (the operative § 103 grounds), the primary reference was not a patent at all:

• Ex. 1003 — FDA Peripheral & Central Nervous System Drugs Advisory Committee, Transcript and Slides (June 6 / July 13, 2001).
• Ex. 1004 — Mani, FDA Preliminary Clinical Safety Review of NDA 21‑196 (May 3, 2001).
• Ex. 1005 — Xyrem® (sodium oxybate) Briefing Booklet for the FDA Advisory Committee (May 3, 2001).
• Ex. 1006 — Xyrem Prescription and Distribution Process Video and Transcript (Feb. 2, 2001).

These ACA exhibits disclosed the centralized Xyrem distribution program, including: checking a central database for potential abuse; confirming a patient's signed confirmation that he/she understands how GHB is to be used before the first prescription is mailed; and authorizing another pharmacy for patient pick-up (used against claims 3/11). The Board found the ACA taught or suggested most claim-1/9 limitations.

The IPR also used these non-patent and patent secondary references:

• Talk About Sleep (Ex. 1033) — Feb. 12, 2001 interview of Orphan Medical ("central pharmacy that will handle delivery of medicine to the patients") — primary reference for the '730 claims.
• Honigfeld (Ex. 1034) — Clozaril National Registry (1998).
• Elsayed (Ex. 1035) = U.S. 6,045,501 (a cited patent; see §1.3).
• Lilly (Ex. 1010) — see §1.3.
• Korfhage (Ex. 1037), Information Storage and Retrieval (Wiley 1997) — a textbook used for the distributed-database limitation of claims 2 and 10.

Result: Claims 1, 3–9, 11–15 of the '988 patent were held obvious over the ACA; claims 2 and 10 over ACA + Korfhage. Affirmed 895 F.3d 1347 (Fed. Cir. 2018).

3. § 102 anticipation assessment — bottom line by claim

Conclusion: Under a strict § 102 analysis, no listed patent citation anticipates any claim of the '988 patent. The examiner himself reached this conclusion for the "exclusive central pharmacy/database" limitation, which is the reason the claims issued. The patent's eventual invalidation was a § 103 obviousness determination driven by the FDA Advisory Committee Art (with Elsayed, Lilly, and Korfhage as secondary references). The most relevant patent citations, in descending order, are:

1. US 6,045,501 (Elsayed / Celgene) — registration + education + pre-fill database check
2. US 6,315,720 (Williams / Celgene) — restricted distribution, risk groups, monitoring
3. US 6,952,681 and US 2002/0042762 (McQuade / Data Reduction Systems) — centralized real-time tracking/authorization of controlled articles
4. US 2003/0093295 (Lilly) — controlled-substance tracking (the "Lilly" secondary reference)
5. US 2004/0117126 (Fetterman) — pharmaceutical risk assessment/management

4. Discrepancies / items I flag explicitly

1. § 102 vs § 103 mismatch. The question presumes § 102 anticipation is the operative frame; the record shows the '988 claims fell under § 103 (obviousness). I have not represented the art as anticipatory where it was not.
2. Priority date. Google Patents lists 2002‑12‑17; the Unified Patents portal lists 2002‑12‑16. Reported literally, not reconciled.
3. "Lilly" exhibit mapping (unverified). I identify the examiner-cited US 2003/0093295 A1 (Ralph B. Lilly) as the likely "Lilly" reference, but I could not definitively confirm the IPR exhibit numbering within my tool budget.
4. Self-citation. US 2005/0090425 A1 (Orphan Medical) is the family's own parent publication and is not independent prior art.
5. Incomplete enumeration. The supplied full text truncates the "Patent Citations (62)" list; the table above covers everything visible in both the "Citations (44)" and "Patent Citations (62)" lists. A definitive count would require pulling the citation list directly from USPTO PatentCenter / the patent's front page.
6. CAFC 2026 activity. Per my earlier section, I found no 2026 Federal Circuit docket naming the '988 patent; the controlling appellate decision is the July 13, 2018 affirmance (895 F.3d 1347). If a definitive "no 2026 activity" confirmation is needed, verify directly against PACER/CAFC dockets for the exact number.

Sources used: Full text of US8457988B1 (Google Patents); Unified Patents portal entry for US‑8457988‑B1; PTAB Final Written Decision, IPR2015‑00551/IPR2015‑00554 (via ipwatchdog.com and paragraphfour.com); IPR2015‑00551 Institution Decision and Petition excerpts (ptacts.uspto.gov, docketalarm.com); US 6,315,720 and US 6,952,681 bibliographic/abstract data (Google Patents, EPO GPI, DrugPatentWatch); search-result snippets for the Celgene and Data Reduction Systems references.

I'll ground this analysis in the actual prior-art record for the '988 patent — particularly the references the PTAB relied on — before constructing the combination analysis.

Let me pull the Federal Circuit's treatment of the '988-specific limitations and the secondary references (Lilly, Elsayed, Honigfeld, Celgene/STEPS).

Obviousness Analysis — U.S. Patent No. 8,457,988 (35 U.S.C. § 103)

Building on the previously generated summary and litigation sections. This analysis does not repeat the bibliographic, continuity, or docket material already presented; it takes those as given and adds the substantive § 103 work-up.

I. Threshold notes before the analysis

A. This is a retrospective validity analysis. As established in the prior sections, claims 1–15 of the '988 patent were held unpatentable by the PTAB in IPR2015-00551 (Final Written Decision, Paper 70, July 27, 2016) and that decision was affirmed in Jazz Pharmaceuticals, Inc. v. [Amneal Pharmaceuticals, LLC](/litigations/by-plaintiff/Amneal%20Pharmaceuticals%2C%20LLC), 895 F.3d 1347 (Fed. Cir. 2018) (opinion at govinfo, USCOURTS-ca13-17-01675). The patent also expired on its anticipated date of 2022-12-17. The analysis below therefore explains why the claims fell, and what a challenger would need to show — it is not a prediction of live litigation risk.

B. Pre-AIA § 103 governs. The '988 application claims priority to December 17, 2002, so the pre-Leahy-Smith AIA version of §§ 102/103 applies. The critical date for § 102(b) purposes is December 17, 2001.

C. The "Prior Art section" of the patent page. The Google Patents record for US8457988B1 lists 44 examiner/third-party citations, and the prior-art keyword set is prescription drug / company / exclusive / patient / database. Those 44 references are addressed in Part VI below. The references that actually did the work in the IPR/CAFC proceeding — the Advisory Committee Art ("ACA"), Korfhage, Talk About Sleep, Honigfeld, Elsayed, and Lilly — are non-patent literature and therefore do not appear in the patent's citation list. I treat both bodies of art, since the task asks for combinations that would render the claims obvious, and the ACA-based combination is the one adjudicated.

D. Flagged discrepancy (carried forward, not auto-corrected). The Google Patents record states priority 2002-12-17; the Unified Patents portal entry states 2002-12-16. Both are reported literally. Nothing in the § 103 analysis turns on the one-day difference.

II. Level of ordinary skill in the art

The Board found the POSA to be a pharmacist or computer scientist having familiarity with computerized drug distribution procedures ('730/'988 Decision, 2016 WL 7985458, at *4–5). This matters because it means the POSA is a person who (a) knows the controlled-substance regulatory landscape (DEA registration, state boards, Schedule III handling) and (b) knows standard database architecture. Jazz's attempt to narrow the POSA to a drug-distribution specialist only was rejected, both by the Board and on appeal. A POSA defined this broadly makes the "motivation to look in the Federal Register / FDA website" finding much easier to sustain.

III. Combination A — The ACA standing alone (the ground that prevailed)

A. What the ACA is

Four documents generated for and by the FDA Peripheral & Central Nervous System Drugs Advisory Committee meeting on Xyrem (sodium oxybate), publicly accessible on the FDA website linked from the May 14, 2001 Federal Register notice, no later than October 4, 2001:

Because all four issued from a single public meeting about a single proposed restricted distribution program for a single drug — and were linked from a single FDA web page — the Board found "ample motivation to combine the ACA documents" (and Jazz did not contest that point at the CAFC). This defeats the usual "separate references, hindsight combination" defense: the ACA is functionally one disclosure.

B. Element-by-element map to claim 1

C. The "only pharmacy and database in existence" limitation — the crux

This is the strongest non-obviousness argument available on claim 1 (and it was pressed early: the patent owner argued the closest art "does not teach or fairly suggest that all prescriptions for GHB are processed only by the exclusive central pharmacy using only the exclusive computer database"). The Board rejected it because the ACA's own framing is exclusivity-by-construction: a single specialty pharmacy is the sole channel, it holds all the data, and Xyrem is not distributed through retail pharmacy. Formulated in the claim's absolutist terms ("the only pharmacy and database in existence"), the limitation adds wording, not a technical step. Under KSR, "the combination of familiar elements according to known methods is likely to be obvious when it does no more than yield predictable results." Note also that in the parallel D.N.J. litigation the court declined to read "exclusive" as requiring Roxane's proposed "and no other" gloss (D.N.J. 2:10-cv-06108, Doc. 151 at 34–36) — i.e., the exclusivity language was not given the narrowing force Jazz wanted.

D. Claim 9 — the "inventory owned by a company" variant

Claim 9 is textually parallel to claim 1 except that the exclusivity element is framed on company ownership of the prescription-drug inventory rather than on the drug being "distributed by a company that obtained approval." The Board treated claims 9–15 in parallel with claims 1–8 and did not treat the inventory-ownership phrasing as a separate patentable distinction. Caveat: in the materials I retrieved I did not find a specific ACA page cite directed to inventory ownership of the Xyrem consignment stock; the record support I can confirm goes to the consignment/centralized inventory character of the program (Ex. 1005, Briefing Booklet) and to the confidential-safety-and-security storage descriptions. A challenger should pin this element with the manufacturer-sponsor disclosures (Orphan Medical as sponsor, single manufacturing site, specialty-pharmacy channel), which the ACA and Talk About Sleep both describe. Flagging this as the weakest-documented element rather than asserting a cite I did not verify.

IV. Combination B — ACA + Korfhage (dependent claims 2 and 10)

Korfhage, Information Storage and Retrieval (John Wiley & Sons 1997) — a general text. Chapter 12 ("Document Access"), § 12.4 ("Distributed Document Systems") opens: "[c]ost, efficiency, and the [sheer] number of documents being published are driving information systems to the use of distributed document sets and distributed processing," and explains that a user prefers "to view the system as accessing a single logical database in response to a query, even when the system must consult multiple physical databases."

Claims 2/10 add: the pharmacy/database "distributed over multiple computers, and wherein a query operates over all data in all the distributed databases relating to the prescriptions, the doctors, and the narcoleptic patients."

Motivation to combine (KSR factors):

1. Known technique to improve a similar method in the same way. Korfhage discloses distributed processing as one of a small set of known database architectures; applying it to the ACA's centralized database is "the use of a known technique to improve a similar device (method, or product) in the same way."
2. Problem recognized in the field, finite solutions. The ACA itself supplies the volume problem (thousands of prescribing forms; "all the data about inventory, physicians, reimbursement, patients, and delivery"). Korfhage supplies the solution direction (cost/efficiency/volume → distributed processing) and expressly preserves the single-logical-database query semantics that claim 2/10 requires.
3. No teaching away. Jazz argued Korfhage listed "three major problems" with multiple physical databases. The Board and the district-court-stage record rejected this: Korfhage pairs each problem with a disclosed solution, which under DePuy Spine v. Medtronic and In re Fulton is at most a preference, not a disparagement. The Board specifically credited Dr. Valuck's testimony that "distributed processing" was "a standard design for a single database to be distributed among multiple computers where the database queries over all the data."
4. No requirement of shared field of endeavor. Korfhage need not relate to pharmacy practice; it supplies an architectural teaching the POSA (a pharmacist or computer scientist) would apply.

The Board found claims 2 and 10 obvious over ACA + Korfhage, and the Federal Circuit affirmed (the distributed-database dependent limitations were expressly among the upheld findings).

V. Combination C — Talk About Sleep + Honigfeld + Elsayed (+ Lilly)

This was the alternative ground asserted for the '730 and '988 patents, and it is worth treating carefully because it did not survive institution on the '730 patent: "we are not persuaded Petitioner has shown a reasonable likelihood of prevailing in its assertion of unpatentability of the '730 patent claims as obvious over TAS, Honigfeld, Elsayed, and Lilly." The Board instituted only on the ACA grounds. This is an honest limit on the combination's proven strength, and the final written decision for the '988 rests on the ACA (+ Korfhage), not on this combination.

Motivation: all four are in the same field (restricted distribution of abuse-prone prescription drugs) and address the same regulatory problem; the modification amounts to "combining prior art methods according to known methods to yield predictable results" — specifically, replacing TAS's fax-based central-pharmacy intake with the computerized centralized registration of Honigfeld/Elsayed, to gain "rapid transmission of information" and centralization of prescription data with the party responsible for controlled distribution. This is the classic KSR "improve a known method with a known technique" rationale. Its evidentiary weakness (which caused the institution denial) was proof that TAS/Honigfeld/Elsayed together disclose the stepped claim-1 sequence, particularly the exclusivity step.

VI. Combinations from the patent's own "Prior Art" citation list (backup / cumulative art)

The 44 references the patent itself cites supply cumulative support for discrete limitations, and several were actually used by examiners against later members of this family (e.g., in the file history of application 14/219,904). The most probative:

Why these combine: they are all directed to the same problem (controlled, auditable, centrally-managed dispensing of drugs, with particular attention to substances subject to abuse, fraud, or contraindication), and each contributes a discrete, self-contained function to a known workflow. Under KSR, "[i]f a person of ordinary skill can implement a predictable variation, § 103 likely bars its patentability."

VII. The overarching motivation-to-combine story

Three independent rationales support the combinations above, and each was endorsed at some stage:

1. Regulatory compulsion / design driver. GHB was known as a "date-rape drug" AND as the approved cataplexy therapy; FDA's advisory committee convened specifically on risk management. A POSA focused on distribution/safety/abuse had a documented reason to look to FDA-generated risk-management material and to the pre-existing restricted-distribution programs for Accutane, Clozaril, and thalidomide/STEPS. The Federal Circuit upheld the Board's finding that this supplied "sufficient motivation to have located the Federal Register Notice and FDA website for Xyrem."
2. Same-problem, same-field combination. The ACA documents are one program; the secondary references (Korfhage aside) all concern restricted distribution of abuse-prone drugs. Combining them is "combining prior art methods according to known methods to yield predictable results."
3. Known technique to improve a known method. Korfhage's distributed processing improves the ACA's centralized database in the same way, and preserves single-query semantics.

VIII. Dependent claims 3–8 / 11–15

IX. Secondary considerations — why Jazz could not carry them

The record (Petitioner's briefing, credited in the ACA-based decisions) shows each Graham secondary factor failing or being weak:

• No nexus. Xyrem's commercial success is attributable to the pharmaceutical effect of the active ingredient and to the ACA-disclosed centralized distribution already in the prior art, not to "what is both claimed and novel" (In re Kao; Dippin' Dots v. Mosey). Orphan's own Briefing Booklet stated the risk-management program would "eliminate[] the opportunity to 'fill the retail distribution pipeline'" — i.e., the program was not sales-driving.
• Regulatory-driven, not inventive. The program was created because FDA required it as a condition of approval; Orphan's own prosecution statements conceded the application "was borne out of this FDA approval process." Merck v. Teva and Friskit make such regulatory-driven success weak.
• No long-felt unmet need / no failure of others. Effective restricted-distribution programs (Accutane, Clozaril, thalidomide/STEPS) existed by December 2002 and were successful in preventing the relevant harms.
• No technical advance required. All claim limitations existed in the art; nothing required an advance in technical knowledge.

X. Where a defender would still push — and my confidence levels

1. "Only pharmacy and database in existence" (claims 1 and 9). The single best non-obviousness argument. It failed at the PTAB/CAFC because the ACA describes a single national specialty pharmacy holding all Xyrem data. A defender would need art-distinguishing evidence that the ACA contemplated additional channels. I found none.
2. "Periodic reports" (claims 1 and 9). Jazz argued the ACA teaches only ad hoc, request-driven reports. The Board construed "periodic" to mean "generated at regular intervals or intermittently" and rejected Jazz's narrower reading; Jazz's challenge to that construction was among the issues on appeal and the affirmance stands. Note the '988 claim does not contain the "current pattern or anticipated pattern" language that claim 27 of the '963 patent did, so the '988 "periodic reports" issue is the narrower one.
3. Claim 9's "inventory owned by a company." As flagged in Part III.D, I did not verify a specific ACA cite for inventory ownership. This is the element I would most want to see buttoned up in any renewed challenge.
4. Claims 3 / 11 ("dispensing by another pharmacy"). Board-credited but I could not retrieve the underlying ACA cite. Flagged.
5. Combination C (TAS + Honigfeld + Elsayed + Lilly). Asserted but not instituted; a challenger should not lead with it.

Explicit uncertainty statements:

• I did not independently read the full text of Korfhage, Honigfeld, Elsayed, TAS, or Lilly; my characterizations derive from the PTAB institution decision, the final written decision, the Federal Circuit opinion, and the IPR petitions as quoted in the search results cited above.
• I could not confirm the exact Federal Circuit docket number(s) mapping to the '988 portion of the appeal (sources reference 2017-1671 and 2017-1675; the govinfo opinion file retrieved is ca13-17-01675), consistent with the caveat already noted in the litigation section.
• I found no 2026 CAFC or PTAB activity naming 8,457,988, consistent with the earlier section's finding and with the patent's expiry.

XI. Bottom line

The '988 claims were obvious under § 103 on a single dominant combination:

ACA (Exs. 1003–1006) alone → claims 1, 3–9, 11–15
ACA + Korfhage → claims 2 and 10

That combination works because the ACA is effectively one prior-art disclosure of the very system the patent claims (single national pharmacy, centralized database, credential verification against DEA/state sources, pre-shipment patient-education confirmation, database abuse checks, conditional dispensing, closed-loop receipt confirmation, and queryable prescriber/patient/dose reporting), and because the only genuinely additional element — distributing the database across multiple computers with a query over all data — was a known design option set out in Korfhage for precisely the cost/efficiency/volume reasons the ACA's own program would have generated.

Secondary, cumulative combinations — TAS + Honigfeld + Elsayed (+ Lilly) for the computerized centralized-registration architecture, and the patent's own cited art (Celgene '501/'720, Lilly '295, Moradi '794, Fetterman '126, Eidex '519, McQuade '762/'681) for discrete limitations such as prescriber-eligibility gating, abuse-pattern shipment blocking, and risk-management-program administration — reinforce the same conclusion and independently confirm that every element had a known analogue in the restricted-drug-distribution art well before December 17, 2002.